Improved Detection of Residual Peritoneal Metastases with Pegsitacianine Imaging Agent

Use of pegsitacianine, a pH-sensitive imaging agent, detected residual disease in 50% of patients undergoing cytoreductive surgery. Pegsitacianine showed high sensitivity, improved surgeon assessment, and had acceptable safety profile. This agent has the potential to enhance detection of residual disease and improve outcomes in peritoneal carcinomatosis patients.